Compare Pfizer Inc (PFE) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Williams-Sonoma, Inc. — how do they compare? Pfizer Inc trades at $27.77 (market cap $158.56B), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Pfizer Inc is far larger — about 5.6× Williams-Sonoma, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Williams-Sonoma, Inc. for 59 Days on average.
| PFE | WSM | |
|---|---|---|
Market Cap | $158.56B | $28.15B |
Volume | 44,138,282 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $251.81 |
52-Week Low | $23.67 | $168.64 |
Typical Hold Time | 158 Days | 59 Days |
Enterprise Value | $210.06B | $28.65B |
Dividend Yield | 6.18% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical signal and strong profitability metrics. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights market share gains, margin expansion, and new store openings, reinforcing positive business momentum.
The outlook remains favorable given earnings outperformance and raised guidance, though valuation multiples are elevated. Key risks include housing market sensitivity and competitive pressures. Analyst consensus is mixed but leans positive, with a price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
